Pharmacy World and Science

, Volume 26, Issue 5, pp 253–255 | Cite as

Pharmacogenetics in health-care practice

  • Anke-Hilse Maitland-van der Zee
  • Olaf H. Klungel
  • Anthonius de Boer
Health care Pharmacogenetics Pharmacy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002; 24: 46–54.CrossRefPubMedGoogle Scholar
  2. 2.
    Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279:1200–5.PubMedGoogle Scholar
  3. 3.
    Steimer W, Potter JM. Pharmacogenetic screening and thera-peutic drugs. Clin Chim Acta 2002; 315: 137–55.Google Scholar
  4. 4.
    Nebert DW, Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet 1999; 56: 247–58.CrossRefPubMedGoogle Scholar
  5. 5.
    van der Weide J, Steijns LS. Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann Clin Biochem 1999; 36: 722–9.PubMedGoogle Scholar
  6. 6.
    Bullock P. Viewpoint-pharmacogenetics and its impact on drug development. Drug Benefit Trends 1999; 11: 53–54.Google Scholar
  7. 7.
    Bailey D, Bondar A, Furness LM. Pharmacogenomics-it's not just pharmacogenetics. Curr Opin Biotechnol 1998; 9: 595–601.CrossRefPubMedGoogle Scholar
  8. 8.
    Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39: 533–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Steen VM. Non-functional CYP2D6 alleles and risk for neurolep-tic-induced movement disorders in schizophrenic patients. Psy-chopharmacology (Berl) 1997; 131: 174–9.Google Scholar
  10. 10.
    Schillevoort I, de Boer A, van der Weide J, Steijns LSW, Roos RAC, Jansen PAF, Leufkens HGM. Antipsychotic-induced extrapyrimi-dal syndromes and cytochrome P450-2D6 genotype. Pharma-cogenetics 2002; 12: 235–40.Google Scholar
  11. 11.
    McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic poly-morphism of thiopurine methyltransferase and its clinical rele-vance for childhood acute lymphoblastic leukemia. Leukemia 2000; 14 (4): 567–72.CrossRefPubMedGoogle Scholar
  12. 12.
    Corominas H, Baiget M. Clinical utility of thiopurine s-methyl-transferase genotyping. Am J Pharmacogenomics 2004; 4 (1): 1–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Mancinelli L, Cronin M, Sadee W. Pharmacogenomics: the promise of personalized medicine. AAPS Pharmsci 2000; 2: 4.CrossRefGoogle Scholar
  14. 14.
    Arranz M, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M et al. Pharmacogenetic prediction of clozapine respons. Lancet 2000; 355: 1615–16.CrossRefPubMedGoogle Scholar
  15. 15.
    Cohen BM, Bongard V. Polymorphisms of the dopamine D4 re-ceptor and response to antipsychotic drugs. Psychopharmacol-ogy (Berl) 1999; 141: 6–10.CrossRefGoogle Scholar
  16. 16.
    Nakagawa, K, Ishizaki T. Therapeutic relevance of pharmacoge-netic factors in cardiovascular medicine. Pharmacol Ther 2000; 86: 1–28.CrossRefPubMedGoogle Scholar
  17. 17.
    Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-con-traceptive users who are carriers of factor V Leiden mutation [see comments]. Lancet 1994; 344: 1453–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Roses AD. Pharmacogenetics and future drug development and delivery. Lancet 2000; 355: 1358–61.CrossRefPubMedGoogle Scholar
  19. 19.
    Carmena R, Roederer G, Mailloux H, Lussier-Cacan S, Davignon J. The response to lovastatin treatment in patients with hetero-zygous familial hypercholesterolemia is modulated by apolipo-protein E polymorphism. Metabolism 1993; 42: 895–901.CrossRefPubMedGoogle Scholar
  20. 20.
    Maitland-van der Zee AH et al. Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes. Pharmacogenetics 2003; 13: 219–23.CrossRefPubMedGoogle Scholar
  21. 21.
    Poirier J et al. Apolipoprotein E4 allele as a predictor of choliner-gic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 1995; 92: 12260–4.PubMedGoogle Scholar
  22. 22.
    Maitland-van der Zee A, de Boer A, Leufkens HGM. Pharmaco-genetics and the role of the pharmacist. Journal of Research in Pharmaceutical Economics 2001; 11: 143–150.CrossRefGoogle Scholar
  23. 23.
    Melzer D, Zimmern R. Genetics and medicalisation. BMJ 2002; 324: 863–4.CrossRefPubMedGoogle Scholar
  24. 24.
    Brock TP et al. Pharmacogenomics: implications and considera-tions for pharmacists. Pharmacogenomics 2003; 4: 321–30.CrossRefPubMedGoogle Scholar
  25. 25.
    Report Pharmacogenetics: ethical issues, September 2003. (5 August 2004).Google Scholar
  26. 26.
    Veenstra DL, Higashi MK, Philips KA. Assessing the cost-effec-tiveness of pharmacogenomics. AAPS Pharmsci 2000; 2: article 29.CrossRefGoogle Scholar
  27. 27.
    Maitland-van der Zee AH et al. Economic evaluation of testing for angiotensin converting enzyme (ACE) genotype before start-ing HMG-CoA reductase therapy in men. Pharmacogenetics 2004; 14: 1–8.PubMedGoogle Scholar
  28. 28.
    Vandenbroucke JP et al. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ 1996; 313: 1127–30.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Anke-Hilse Maitland-van der Zee
    • 1
    • 2
  • Olaf H. Klungel
    • 1
    • 2
  • Anthonius de Boer
    • 1
    • 2
  1. 1.Department of Pharmacoepidemiology & Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences (UIPS)Utrecht UniversityUtrechtThe Netherlands
  2. 2.Human Genetics CenterUniversity of Texas Health Science CentreHoustonUSA E-mail

Personalised recommendations